[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355093-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355093-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-associated-fibroblasts-enablers-of-tumor-drug-resistance","Cancer-associated fibroblasts: enablers of tumor drug resistance","","Treatment failure from drug resistance acts as a major roadblock to effective cancer cure. Research increasingly highlights the tumor microenvironment (TME) as a critical driver of malignant progression and therapeutic resistance. Within the TME, cancer-associated fibroblasts (CAFs) are highly prevalent and plastic, shaping resistance through soluble factors, metabolites, extracellular matrix remodeling, immune regulation, and cell-death control. The review integrates evidence and summarizes advances in CAF-targeted nanotherapeutic strategies and their mechanisms, while noting remaining barriers to clinical translation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-associated-fibroblasts-enablers-of-tumor-drug-resistance/355093/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-associated-fibroblasts-enablers-of-tumor-drug-resistance/355093.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is drug resistance a major challenge in cancer therapy?","Question",{"text":63,"@type":64},"Drug resistance causes treatment failure and blocks curative outcomes. It has remained a substantial obstacle despite progress in radiotherapy, chemotherapy, and hormone therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do cancer-associated fibroblasts (CAFs) play in therapeutic resistance?",{"text":68,"@type":64},"CAFs are key components of the tumor microenvironment and contribute to resistance by secreting soluble factors and metabolites, remodeling the extracellular matrix, and regulating immune responses and cell death.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review suggest about targeting CAFs with nanotherapies?",{"text":72,"@type":64},"Nanotherapeutic strategies targeting CAFs show considerable promise for improving treatment efficacy. Further research is still required to support clinical translation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355093,1790201143,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":104,"preview_page_count":33,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Chen et al. Journal of Translational Medicine (2026) 24:263  \n[https://doi.org/10.1186/s12967-025-07643-4](https://doi.org/10.1186/s12967-025-07643-4)  \nJournal of Translational Medicine  \nREVIEW Open Access  \nCancer-associated fibroblasts: enablers of tumor drug resistance  \nYanting Chen1, Wei Xi1, Xingyue Lai1, Linglin Xiang1, Anqi Zeng2* and Linjiang Song1*  \nAbstract  \nBackground Treatment failure due to drug resistance has always been a “roadblock” to cancer cure. For a long time, drug resistance research has focused on the nature of the cancer cells themselves; however, more and more studies have found the non-negligible significance of the tumor microenvironment (TME) in cancer malignant progression and therapeutic resistance. Within the TME, cancer-associated fibroblasts (CAFs) represent the most prevalent and highly plastic cells, exerting profound influence on tumor progression.  \nMethods We integrate recent literature and synthesize evidence from both preclinical and clinical studies to elucidate the potential mechanisms by which CAFs contribute to therapeutic resistance and to summarize up-to-date research developments in nanotherapeutic strategies targeting CAFs.  \nResults Emerging findings demonstrate that CAFs substantially contribute to drug resistance by secreting various soluble factors and metabolites, remodeling the extracellular matrix (ECM), and regulating immune responses and cell death. Nanotherapeutic strategies show considerable promise in improving treatment efficacy, while further research is required to facilitate their clinical translation.  \nConclusions CAFs act as key orchestrators ofthe drug-resistant TME, positioning them as compelling targets for next-generation anticancer strategies. Moreover, advancing progress in nano-strategies targeting CAFs holds substantial promise for improving clinical outcomes in cancer therapy.  \nKeywords Cancer-associated fibroblasts, Tumor microenvironment, Resistance, Nanoparticles  \n*Correspondence: Anqi Zeng [zeng6002aq@163.com](zeng6002aq@163.com)[ ](zeng6002aq@163.com)Linjiang Song  \n[songlinjiang@cdutcm.edu.cn](songlinjiang@cdutcm.edu.cn)  \n1School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P. R. China 2Translational Chinese Medicine Key Laboratory of Sichuan Province, Sichuan Academy of Chinese Medicine Sciences, Sichuan Institute for Translational Chinese Medicine, Chengdu, Sichuan 610041, P. R. China  \nBackground  \nCancer continues to represent a significant global health concern, with the latest statistics reporting approximately 20 million new cases and 9.7 million cancer-related deaths worldwide in 2022 [1]. Although advances in current therapies such as radiotherapy, chemotherapy, and hormone therapy have improved treatment efficacy, the development of cancer resistance continues to pose a substantial obstacle to achieving curative outcomes.  \nPaget first proposed the “seed and soil” theory in 1889 [2], highlighting the critical role of tumor microenvironment (TME) in tumor progression. In recent years, increasing research attention on the TME has underscored its indispensable contribution to drug resistance.  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence","cbCainePKWl8yG6y","https://ap.wps.com/l/cbCainePKWl8yG6y","pdf",1848831,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Correspondence","[{\"question\":\"Why is drug resistance a major challenge in cancer therapy?\",\"answer\":\"Drug resistance causes treatment failure and blocks curative outcomes. It has remained a substantial obstacle despite progress in radiotherapy, chemotherapy, and hormone therapy.\"},{\"question\":\"What role do cancer-associated fibroblasts (CAFs) play in therapeutic resistance?\",\"answer\":\"CAFs are key components of the tumor microenvironment and contribute to resistance by secreting soluble factors and metabolites, remodeling the extracellular matrix, and regulating immune responses and cell death.\"},{\"question\":\"What does the review suggest about targeting CAFs with nanotherapies?\",\"answer\":\"Nanotherapeutic strategies targeting CAFs show considerable promise for improving treatment efficacy. Further research is still required to support clinical translation.\"}]","Cancer-associated fibroblasts: enablers of tumor drug resistance | PDF",1790115941,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83c6ef1ee15f92358bba61e3bea6ca0c.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e39310c26a831ac55123b1d94fba980e.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3a51925a2d0db0710407f6c6676affd.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc585bd76e4604278555b90b518a3ea2.webp",980,1306]